Abstract: The present specification discloses TEMs, compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, methods of treating a smooth muscle disorder in an individual using such compositions, use of such TEMs in manufacturing a medicament for treating a smooth muscle disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating a smooth muscle disorder, use of such TEMs in treating a smooth muscle disorder, and use of such TEMs and Clostridial toxins in treating a smooth muscle disorder.

Abstract: The present specification discloses TEMs, compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, methods of treating an involuntary movement disorder in an individual using such compositions, use of such TEMs in manufacturing a medicament for treating an involuntary movement disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating an involuntary movement disorder, use of such TEMs in treating an involuntary movement disorder, and use of such TEMs and Clostridial toxins in treating an involuntary movement disorder.

Abstract: The present specification discloses TEMs, compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, methods of treating a neuroendocrine disorder in an individual using such compositions, use of such TEMs in manufacturing a medicament for treating a neuroendocrine disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating neuroendocrine disorder, use of such TEMs in treating a neuroendocrine disorder, and use of such TEMs and Clostridial toxins in treating a neuroendocrine disorder.

Abstract: The present specification discloses TEMs, compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, methods of treating a cosmesis disorder in an individual using such compositions, use of such TEMs in manufacturing a medicament for treating a cosmesis disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating a cosmesis disorder, use of such TEMs in treating a cosmesis disorder, and use of such TEMs and Clostridial toxins in treating a cosmesis disorder.

Abstract: The present specification discloses methods of treating a sensory disturbance disorder in an individual using Targeted Endopeptidase Modulators (TEMs), compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, use of such TEMs and/or Clostridial toxins in manufacturing a medicament for treating a sensory disturbance disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating a sensory disturbance disorder, use of such TEMs in treating a sensory disturbance disorder, and use of such TEMs and Clostridial toxins in treating a sensory disturbance disorder.

Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.

Abstract: The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, stereoisomer or racemic mixture thereof. Stress-associated conditions that can be treated according to a method of the invention include, but are not limited to, dyspepsia, tachycardias other than tachycardia associated with myocardial ischemia, panic attack, non-inflammatory dermatological conditions, disorders of muscle contraction, sensory hypersensitivity associated with migraine, and behavioral disorders.

Abstract: A method for treating a mammary gland disorder, including hyperplastic, hypertonic, cystic and/or neoplastic mammary gland tissue by local administration of a botulinum toxin to or to the vicinity of the afflicted breast tissue.

Abstract: Methods for treating diverse cancers by local administration of a botulinum toxin to or to the vicinity of the cancer.

Abstract: A method for treating a mammary gland disorder, including hyperplastic, hypertonic, cystic and/or neoplastic mammary gland tissue by local administration of a botulinum toxin to or to the vicinity of the afflicted breast tissue.

Abstract: Herein disclosed are methods for treating headache, such as a chronic migraine for example, by administration of botulinum toxin to fixed specific locations of a patient at a fixed amount, as well as optionally administering additional botulinum toxin to a subset of the fixed specific locations of a patient to treat the headache.

Abstract: Methods for treating melanin related afflictions by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a melanin related affliction.

Abstract: A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache.

Abstract: The present invention features methods for selecting a patient with an enhanced therapeutic response to a botulinum toxin treatment of a headache. In some embodiments, the methods comprise the step of identifying a patient who is not using a prophylactic headache pain medication, a patient who is overusing an acute pain medication, a patient who suffers four or more hours of headache pain per headache, a patient who has a chronic daily headache for twenty or more years, and/or a patient who has twenty or more headache days out of a 30-day-month.

Abstract: Methods of treating humans or animals afflicted with primary blepharospasm, for example, benign essential blepharospasm, or secondary blepharospasm not caused by an ocular surface disease or condition, are component to a human or animal so afflicted.

Abstract: A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache.

Abstract: Methods for treating a coronary risk factor (such as hypertension, diabetes, hyperlipidemia and obesity) and/or a respiratory disorder (such as asthma, chronic obstructive pulmonary disease and bronchitis) and/or arthritis by local administration of a botulinum neurotoxin to at least one of a head, neck or shoulder location (for example, by subdermal, subcutaneous or intramuscular administration of the botulinum neurotoxin) of a patient with a coronary risk factor, respiratory disorder or arthritis.

Abstract: The present specification discloses modified Clostridial toxins, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such modified Clostridial toxins and compositions.

Abstract: The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. Stress-associated conditions that can be treated according to a method of the invention include, but are not limited to, dyspepsia, tachycardias other than tachycardia associated with myocardial ischemia, panic attack, non-inflammatory dermatological conditions, disorders of muscle contraction, sensory hypersensitivity associated with migraine, and behavioral disorders.

Abstract: The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. Stress-associated conditions that can be treated according to a method of the invention include, but are not limited to, dyspepsia, tachycardias other than tachycardia associated with myocardial ischemia, panic attack, non-inflammatory dermatogical conditions, disorders of muscle contraction, sensory hypersensitivity associated with migraine, and behavioral disorders.